Survey: COVID-19 and Adrenal Insufficiency
The CAH Support Group has been working as part of the Adrenal Causes Together (ACT) group for the last 8 months and one of the many positive outcomes of this has been the development of this survey – ‘COVID-19 and Adrenal Insufficiency’.
The survey is to help determine the impact of COVID-19 on people with all forms of adrenal insufficiency from around the world.
We’d like all those with adrenal insufficiency to fill in the survey – not just those who’ve had COVID-19. It will be really helpful if as many people as possible could complete it.
Link to the survey:
https://aicovid2020.questionpro.com/
Recent Blog Posts
What you should know about COVID-19 – updated 10th August 2021
Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 10th August 2021 Article: “ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises”...
New NICE Guidelines – identification and management of adrenal insufficiency
The publication of new NICE (National Institute for Health and Care Excellence) guidelines - "Adrenal insufficiency: identification and management" marks a significant advancement in the management and treatment of primary, secondary and tertiary adrenal...
Survey: Paediatric Adrenal Insufficiency Education
This project, led by Edge Hill University is working with NHS clinicians to develop national education standards and resources for sick day/emergency management of adrenal insufficiency in children and young people. The project would like to hear the views of parents...
Treatment Research Update – Crinetics Atumelnant (CRN04894)
Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. It is an oral, selective ACTH antagonist. Atumelnant is now in Phase 2 of development and you can read the latest...